This multi‐center real‐world data study including 336 Asian patients with advanced BRAF V600‐mutant melanoma showed that the superiority of Anti‐PD‐1/CTLA‐4 over BRAF/MEK inhibitor appears modest, and the BRAF/MEK inhibitor remains a feasible first‐line treatment option. This evidence concerns the gene BRAF and melanoma.